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Efficacy of the treatment with prostaglandin E-1
in venous ulcers of the lower limbs
Glauco Milio, MD,a Chiara Minà, MD,a Valentina Cospite, MD,a Piero L. Almasio, MD,b and
Salvatore Novo, MD,a Palermo, Italy
Background: Venous ulcers represent an important medical problem because of their high prevalence and consequent
sanitary costs. In this study, we evaluated the effect of prostaglandin E-1 (PGE-1), a drug that improves district ischemia,
on the healing of venous ulcers.
Methods: We performed a randomized, placebo-controlled, single blind study in which 87 patients who had venous leg
ulcers homogeneous for dimensions and characteristics were treated for 20 days with an infusion of prostaglandin E-1 or
placebo, in association with topical therapy. The dimension and the number of the ulcers were determined at the
beginning of the treatment and then every 20 days up to 4months, or until total recovery. The main outcome of the study
was the recovery percentage of the ulcers at the end of the 120-day period of observation and the referred healing time.
The reduction in the extension of ulcers from the baseline measurement to the last observation was also evaluated.
Results: The baseline characteristics of the treatment and control groups were similar. The reduction in the size of the
ulcers was faster in the patients treated with PGE-1. In this group, 100% of the ulcers healed <100 days, whereas in the
placebo group, only 84.2% did so by the end of the 120-day observation period (P < .05). The estimated healing times
of 25%, 50%, and 75% of the patients treated with PGE-1 were 23, 49, and 72 days, respectively, compared with 52, 80,
and 108 for the patients in the placebo group. Only one serious event occurred in the treated group.
Conclusions:This study demonstrates the effectiveness of PGE-1 in reducing the healing time of venous ulcers, suggesting
that venous ulcers should also be considered ischemic. ( J Vasc Surg 2005;42:304-8.)Venous ulcers represent an important problem from
both a medical and socioeconomic point of view. In fact,
they have a prevalence of 0.25% to 1.25% in the general
population because of their poor tendency to heal,1-4 and
the costs are high in terms of sanitary expenditure, invalid-
ity, and absence from work.5-7
The origin of venous ulcers is controversial but cer-
tainly multifactorial.8 On the one hand, they are closely
related to hemodynamic disorders leading to venous hyper-
tension and stasis9,10; on the other, they are connected with
microcirculatory alterations, and in this context, the “fibrin
cuffs” observed by Browse et al,11 Burnard,12 and Van der
Scheur et al,13 and the “white cells trapping”14 described
by Coleridge-Smith et al15 and Thomas et al16 certainly
play a fundamental role. Whatever mechanism is responsi-
ble for the production and the evolution of venous ulcers,
they are certainly the final expression of the upset of a
metabolic and coagulative equilibrium involved in the
maintenance of normal cutaneous trophism. A condition of
chronic district hypoxia17 breaks this equilibrium, leading
to a cascade of events that produce the venous ulcers.
Previous studies demonstrated anti-ischemic effects
of some drugs on venous ulcers.18-24 Prostaglandin E-1
(PGE-1), a metabolite of the polyunsaturated dihomo-
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304gamma-linoleic acid, is one of these drugs and plays a
central role. It is not only a constituent of membrane
phospholipids but it also acts mainly on membrane re-
ceptors on the intercellular adenyl-cyclase, producing a
consequent increase in cyclic adenosine monophosphate
that is able to carry out numerous actions, as reported in
Table I.25-35
Starting from these assumptions, we conducted a study
to determine if pharmacologic treatment with PGE-1, in
association with elastic compression and local therapy, has a
favorable effect on the healing of venous ulcers.
METHODS
Study design. In a randomized, single-blinded, pla-
cebo-controlled trial, we evaluated the effect of PGE-1 in
reducing the healing time in 87 consecutive patients who
had venous ulcers of the lower limbs without complica-
tions. The patients were randomized into two groups. The
Table I. Pharmacologic effects of prostaglandin E-1
● reduction of the adhesiveness and platelet aggregation
● inhibition of the proliferation of the smooth muscle cells of
the media
● reduction of the hematic viscosity
● profibrinolytic effect
● inhibition of the chemiotaxis and the activation of white cells
● restoration of the equilibrium between the microvascular flow
regulating system and the microvascular defense system, with a
reduction of the endothelial permeability and inhibition of the
vasoconstrictive activity of thromboxane A2, serotonin,
leukotrienes, and endothelin
● stimulation of formation and growth of collateral circulationallocation sequence was obtained using a random-number
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was received PGE-1 (Prostavasin, Schwarz Pharma) at 60
mg/day in 250 mL of saline solution administered by
venous infusion at about 120mL/h (about 2 h/day) for 20
days. The placebo group (43 patients) received a venous
infusion of a saline solution with analogous characteristics
of duration and quantity.
Both groups were also treated with elastic bandaging
and local therapy. The elastic bandaging was done with a
short, stretch bandage applied with different levels of com-
pression according to the different hemodynamic charac-
teristics of the ulcers (depending on the prevalent alter-
ations in the superficial or deep venous system). The
bandage was 8 to 10 cm wide according to current guide-
lines.36 Wound care consisted of regular ulcer cleaning with
saline solution and topical antiseptics. The topical treat-
ment was stopped after the complete cicatrization of the
ulcers or after 4 months.
We were alert for the eventual insurgence of side effects
during the entire period in which the treatment was admin-
istered.
The study complied with the Consolidated Standards
of Reporting Trials (CONSORT) statement.37 The proto-
col was approved by the ethics committee of the University
Hospital “P.Giaccone” of Palermo, and all patients gave
informed consent.
Patients. The trial enrolled patients who had venous
ulcers of the lower limbs, which were defined as any non-
healing wound of the skin of the lower extremities caused
by impaired venous return, without complications. The
patients were between 37 and 75 years old.
The inclusion criteria were the presence of chronic
venous insufficiency, evident clinically and with echo-Dop-
pler evaluation; the presence of one or more ulcers for 1
year, with maximum orthogonal ulcer diameters having a
product between 5 and 30 cm2; an ankle-brachial index
(ABI) ratio0.90 for both limbs, and no contraindications
for the use of PGE-1.
The exclusion criteria included evidence of arterial,
diabetic, or neurotrophic ulcers and all of the possible
pathologic conditions that cause peripheral ulcers, such as
diabetes mellitus, hematologic diseases, neuropathy, arteri-
opathy, and vasculitis; active infection of the ulcers; saphe-
nectomy or sclerotherapy during the last 6 months; ongo-
ing treatment with heparin, antiplatelet drugs, heparinoids,
other vasoactive drugs; and poor patient compliance.
Procedures, measurement, and outcomes. The pa-
tients were examined at the baseline visit and then after 20,
40, 60, 80, 100, and 120 days. They were followed as
outpatients (the patients stayed in the hospital for about 6
hours and then went home).
A clinical examination and an assessment of the ulcers
were performed at each visit. The number and the dimen-
sion of the ulcers were determined. The size of the ulcers
was calculated from contour sheets at a central location by
computerized planimetry using digital scanning and analy-
sis software.Before the study began, an ultrasound study of the
lower limbs, according to current guidelines38 was done on
all the patients to determine the cause of the ulcers (varicose
or post-thrombotic) and to exclude arterial alterations. An
echo color Doppler machine (ATL HDI 1500, Bothell,
Wash) with a 7.5-MHz linear probe was used. Arterial
district evaluation of the lower limbs was performed with
the patients in supine position; blood pressure at the ankle
and the ABI index were measured according to the current
Transatlantic Intersociety Consensus guidelines.39 Venous
district evaluation was performed with the patient in an
orthostatic position to detect the presence of obstructive
lesions (total or partial) and valvular insufficiency in the
femoral, popliteal, and leg veins.
The outcome was the percentage of the ulcers healed at
the end of the 120-day observation period and the referred
time of healing. The reduction in the extension of the ulcers
from the baseline measurement to the last observation was
also evaluated.
Sample size and statistical analysis. The calculation
of sample size for this trial was based on the assumption that
the percentage of healed ulcers at the end of the observa-
tion period would be 80% in the placebo group. Based on
80% power to detect a significant difference (P  .05), we
considered clinically relevant an increase of 25% in the rate
of healed ulcers in the treated group; therefore, the number
of patients to be randomized was 37 in each group.
The analysis of the efficacy endpoints was based on the
intention-to-treat principle. Statistical analysis was per-
formed by using Statistical Package for the Social Sciences
(SPSS) software version 11.0 forWindows (SPSS, Chicago,
Ill). An unpaired Student’s t test was used to compare
continuous variables. The 2 square test and Fisher’s exact
test were used to compare differences between proportions.
Time to recovery was evaluated with the Kaplan-Meier
curve for cumulative ulcer healing over time.40,41 The
statistical comparison between the two groups regarding
the healing time of the ulcers was done with the log-rank
test.41 Nonparametric data were evaluated by using median
as measure of the center of the distribution and interquar-
tile range (IQM) as measure of the spread. Statistical sig-
nificance was stated for P  .05.
RESULTS
A total of 87 consecutive patients were enrolled from
March 2003 to November 2003; 44 were randomized to
the PGE-1 group and the remaining 43 to the placebo
group. These patients were included in the intention-to-
treat analysis. Nine patients (5 from the PGE-1 group, 4
from the placebo group) did not complete the study. Three
withdrew consent, one from the PGE-1 group for the onset
of gastrointestinal side effects, one from the placebo group
for the onset of a cerebral stroke, and the remaining four
missed the successive follow-up visits. Overall 78 patients
(40 from the treatment group and 38 from the placebo
group) completed the study.
As summarized in Table II, the groups were homoge-
neous for demographic characteristics, clinical history, ul-
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therapy, and associated disease.
Outcomes. A progressive reduction in the extension
of the ulcerated wounds was observed in both groups up to
complete cicatrization, which occurred in 40 patients of the
PGE-1 group and in 32 patients of the placebo group. At
the end of the 120-day observation period, the recovery
percentage was 100% in PGE-1 group versus 84.2% in the
placebo group, with a statistically significant difference (P
 .05) in favor of the PGE-1 group.
As is summarized in Table III, these modifications
happened in a shorter period of time in the patients treated
with PGE-1 compared with the other group. After only 40
days, a complete cicatrization of the ulcers occurred in
42.5% of the patients in the treatment group, a percentage
that increased to 67.5% after 60 days, to 85% after 80 days,
and to 100% after only 100 days, before the end of the
observation period. The process was slower in the placebo
group, with a lack of complete healing after 4 months in
seven patients (Tables III and IV).
Fig 1 shows the Kaplan-Meier curve for the cumulative
healing of the ulcers over time. This shows that the esti-
Table III. Number of ulcers healed at various observation
20 days (%) 40 days (%) 60
PGE-1 group 9 (22.5) 7 (42.5) 27
Placebo group 1 (2.6) 5 (13.1) 14
PGE-1, Prostaglandin E-1.





Number of patients 44 43
Age, mean (SD) 53 (20) 57 (15)
Sex, female (%) 25 (56.8) 26 (60.5)
Clinical history, n (%)
VTE 12 (27.3) 10 (23.3)
Sclerotherapy 9 (20.4) 7 (16.3)
Surgery 5 (11.4) 6 (13.9)
Duplex ultrasound findings, n (%)
Total or partial obstruction 21 (47.7) 19 (44.2)
Superficial vein valvular incompetence 37 (84.1) 37 (86)
Deep vein valvular incompetence 23 (52.3) 21 (48.8)
Perforating vein valvular
incompetence
25 (56.8) 21 (48.8)
Sapheno-femoral or sapheno-popliteal
reflux
32 (72.7) 34 (79.1)
Concomitant conditions, n (%)
Arterial hypertension 15 (34.1) 18 (41.8)
Obesity 14 (31.8) 14 (32.6)
Orthopedic diseases 8 (18.2) 6 (13.9)
Ulcer features
Months from ulcer appearance,
median (IQR)
5 (2-10) 5 (2-11)
Ulcer area, cm2 (IQR) 13 (3-25) 11 (4-20)
PGE-1, Prostaglandin E-1; VTE, venous thromboembolism; IQR, inter-
quartile range.*Percentage of healed ulcers over all ulcers for each group.mated healing time of 25%, 50%, and 75% for the patients
treated with PGE-1 was 23, 49, and 72 days, respectively,
compared with 52, 80, and 108 for the patients in the
placebo group, with a statistically significant difference in
favor of the PGE-1 group (P  .001 by log-rank test).
The incidence of adverse events was 11.36% (5 of 44) in
the PGE-1 group, and 4.65% (2 of 43) the in placebo
group. Only one serious event (diarrhea and vomiting)
occurred in the treatment group, such that the patient
could not complete the study. The other side effects were
headache (2 cases), hypotension (1), and nausea (1) in the
PGE-1 group, and hypertension (1) and tachycardia (1) in
the placebo group.
DISCUSSION
In this randomized study, the patients with venous
ulcers were treated with PGE-1 in association with elastic
compression bandage and topical therapy. Color flow
Doppler scanning was used to ensure that only patients
with “pure” venous ulcers were included. In fact, this
method not only made it possible to evaluate the presence
of valvular insufficiency related to primitive varices or post-
thrombotic syndrome, but also allowed us to exclude ulcers
that were ischemic in nature, connected with a reduction in
district arterial flow and also through the Ankle Brachial
Index. The 4-month observation time was sufficiently long
enough to assess the long-term effects.40,42
The study demonstrated that the treatment with
PGE-1 is effective on venous ulcers of the lower limbs. In
fact, this treatment caused a quicker and more frequent
healing, which took place for all the cases 100 days,
before the last evaluation. Furthermore, the estimated heal-
ing time for 75% of the patients was 72 days for the group
treated with PGE-1 versus 108 days for the placebo group,
with a statistically significant difference in favor of the
former group. These data are in accordance with those
reported by Rudofski,43 who demonstrated in a double-
blind controlled study a complete healing of 40% of “resist-
ing” ulcers in short times.
Still to be verified is the mechanism with which PGE-1
favors the healing of venous ulcers. Hemodynamic mecha-
nisms linked to venous hypertension and stasis, on which
PGE-1 does not seem to interfere, take part in the origin of
venous ulcers. However, it is also true that other mecha-
nisms that determine conditions of ischemic suffering are
involved, such as the activation of the white cells, endothe-
lial dysfunction, and the activation of fibrinogenesis, as well
as changes to the cutaneous trophism. In the natural history
of the venous ulcer, this is probably the pathophysiologic
es*
%) 80 days (%) 100 days (%) 120 days (%)
5) 34 (85) 40 (100) 40/40 (100)
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This drug, among other actions, inhibits chemiotaxis and
activation of white cells and is also able to stabilize the
endothelial membrane and activate fibrinolysis, showing a
favorable effect on the evolution of venous ulcers demon-
strated in this research. Furthermore, such effect could also
be related to the local improvement in microcirculation, as
suggested by Rudofski.43
The long-term effects are more difficult to explain. In
fact, one of the pharmacodynamic characteristics of PGE-1
is its poor stability and very brief half-life of about 30
seconds. This contrasts with the clinical efficacy that persists
beyond its administration. This suggests that, on one hand,
the effects could be related to one of its metabolites,
PGE-0, that has a sensibly longer half-life and is biologically
active with analogous efficacy. On the other hand, the
explanation could be found in the numerous actions of
PGE-1. In fact, if its direct effect on the vascular walls
Table IV. Ulcer area, expressed in cm2, at various observa
0 days 20 days 40 days
PGE-1 13.4 (3.2-25.7) 11.2 (2.9-22.3) 8.3 (3.1-17.1)
Placebo 11.7 (4.0-20.6) 10.1 (3.8-19.8) 9.7 (3.6-17.3)
P NS NS .05
PGE-1, Prostaglandin E-1; NS, not significant.
*Median and interquartile range and statistical significance.
Fig 1. Kaplan-Meier curves for cumulative ulcer healing over
time, including all randomized patients.finishes in a few hours, the indirect effect on the fibrinolysisand the leukocytes lasts, longer causing part of the long-
term effects.
Finally, PGE-1 treatment could assume a favorable
cost-benefit ratio even though the economic cost is quite
high. The reduction in the healing times should shorten the
period of hospitalization and allow a quicker return to
work, thus producing an improvement in the quality of life
with positive socioeconomic reflections.44 More studies
performing a cost-benefit analysis are required to verify this
hypothesis.
CONCLUSIONS
The data of this research demonstrate the effectiveness
of PGE-1 in reducing the healing time of venous leg ulcers
and support the idea that venous ulcers must also be
considered “ischemic.” Furthermore, the negative side ef-
fects of treatment with PGE-1 are, on the whole, acceptable
and the drug is well tolerated by the patients.
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